SAU PHARMA

SAU Pharma is a San Francisco-based biotechnology company dedicated to developing innovative therapies for aggressive cancers, with a primary focus on Glioblastoma Multiforme (GBM). The company's lead candidate, SAU-1, is a first-in-class small molecule designed to cross the blood-brain barrier and target specific metabolic vulnerabilities in tumor cells. By disrupting the metabolic pathways that fuel cancer growth, specifically targeting monocarboxylate transporters, SAU Pharma aims to provide a more effective treatment option for patients with limited therapeutic alternatives. The company is currently advancing its lead program through IND-enabling studies and exploring the potential of its approach in other solid tumors. SAU Pharma's research leverages the unique metabolic profile of high-grade gliomas to achieve selective toxicity against cancer cells while sparing healthy brain tissue.